Genomed EBIT/Assets

What does Genomed do? Genomed SA generates revenue through molecular diagnostics services based on DNA sequencing, particularly Next Generation Sequencing (NGS). The company offers gene mutation analysis for over 150 congenital diseases including infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. Their primary clients are healthcare providers and research institutions seeking personalized medicine solutions and genomic technology integration. Genomed SA also provides DNA sequencing, analysis, and synthesis services for the biotechnological market, targeting academic and industrial research sectors. The company's business model focuses on developing advanced diagnostic tools for medical applications, with a strong emphasis on NGS technology. Their service portfolio includes specialized genetic testing for congenital conditions and research-oriented DNA services. By concentrating on personalized medicine and gene treatment clinics, Genomed SA positions itself as a provider of specialized genomic solutions for both clinical and research markets. Genomed SA's revenue streams are derived from diagnostic testing services for congenital diseases and biotechnological DNA services. The company serves healthcare facilities requiring genetic analysis for patient care and research organizations needing genomic data for scientific advancement. Their offerings target medical professionals and biotechnology companies seeking to implement genomic technology in their operations. Genomed is one of the most popular companies on Eulerpool.